Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER METABOLISM

The uninhibited pathway is not worth studying

Glucose 6-phosphate dehydrogenase (G6PD) stands at the head of the pentose phosphate pathway, which is responsible for nucleotide synthesis. The identification and thorough validation of an improved G6PD inhibitor provide a valuable new tool compound for studying metabolism.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The parallel glycolysis and pentose phosphate pathways in a T cell.

References

  1. Horecker, B. L. J. Biol. Chem. 277, 47965–47971 (2002).

    Article  CAS  Google Scholar 

  2. Chen, L. et al. Nat. Metab. 1, 404–415 (2019).

    Article  CAS  Google Scholar 

  3. Marks, P. A. & Banks, J. Proc. Natl Acad. Sci. USA 46, 447–452 (1960).

    Article  CAS  Google Scholar 

  4. Mele, L. et al. Cell Death Dis. 9, 572 (2018).

    Article  Google Scholar 

  5. Preuss, J. et al. J. Biomol. Screen. 18, 286–297 (2013).

    Article  CAS  Google Scholar 

  6. Ghergurovich, J. M. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-020-0533-x (2020).

  7. Stincone, A. et al. Biol. Rev. Camb. Philos. Soc. 90, 927–963 (2015).

    Article  Google Scholar 

  8. Mercaldi, G. F., Ranzani, A. T. & Cordeiro, A. T. J. Biomol. Screen. 19, 1362–1371 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael E. Pacold.

Ethics declarations

Competing interests

M.E.P. is a consultant to and holds equity in Raze Therapeutics and is the recipient of travel funds from Thermo Fisher Scientific.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pacold, M.E. The uninhibited pathway is not worth studying. Nat Chem Biol 16, 713–714 (2020). https://doi.org/10.1038/s41589-020-0562-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41589-020-0562-5

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research